Literature DB >> 27291933

Safety data from randomized controlled trials: applying models for recurrent events.

Johannes Hengelbrock1, Johanna Gillhaus2, Sebastian Kloss2, Friedhelm Leverkus2.   

Abstract

Simple descriptive listings and inference statistics based on 2×2 tables are still the most common way of summarizing and reporting adverse events data from randomized controlled trials, although these methods do not account for differences in observation times between treatment groups. Using standard methods from survival analysis such as the Cox model or Kaplan-Meier estimates would overcome this problem but limit the analysis to the first safety-related event of each subject. As an alternative, we discuss two models for recurrent events data-the Andersen-Gill and Prentice-Williams-Peterson model-regarding their applicability to safety data from randomized controlled trials. We argue that these models can be used to estimate two different quantities: a direct treatment effect on the risk of an event (Prentice-Williams-Peterson) and a total treatment effect as sum of the direct effect and the treatment's indirect effect via the event history (Anderson-Gill). Using simulated data, we illustrate the difference between these treatment effects and analyze the performance of both models in different scenarios. Because both models are limited to the analysis of cause-specific hazards if competing risks are present, we suggest to incorporate estimates of the mean frequency of events in the analysis to additionally allow the comparison of treatment effects on absolute event probabilities. We demonstrate the application of both models and the mean frequency function to safety endpoints with an illustrative analysis of data from a randomized phase-III study.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  adverse events; randomized controlled trials; recurrent events; safety data; survival analysis

Mesh:

Year:  2016        PMID: 27291933     DOI: 10.1002/pst.1757

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  7 in total

1.  Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma: study protocol for a multicentric randomized controlled trial.

Authors:  Ingo Stoffels; Ken Herrmann; Jan Rekowski; Philipp Jansen; Dirk Schadendorf; Andreas Stang; Joachim Klode
Journal:  Trials       Date:  2019-02-04       Impact factor: 2.279

2.  Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.

Authors:  Ralf Bender; Lars Beckmann; Stefan Lange
Journal:  Pharm Stat       Date:  2016-02-29       Impact factor: 1.894

3.  A systematic comparison of recurrent event models for application to composite endpoints.

Authors:  Ann-Kathrin Ozga; Meinhard Kieser; Geraldine Rauch
Journal:  BMC Med Res Methodol       Date:  2018-01-04       Impact factor: 4.615

4.  Limitations of the incidence density ratio as approximation of the hazard ratio.

Authors:  Ralf Bender; Lars Beckmann
Journal:  Trials       Date:  2019-08-08       Impact factor: 2.279

5.  Marginal hazard ratio estimates in joint frailty models for heart failure trials.

Authors:  Gerrit Toenges; Antje Jahn-Eimermacher
Journal:  Biom J       Date:  2019-06-17       Impact factor: 2.207

Review 6.  Statistical methods for the analysis of adverse event data in randomised controlled trials: a scoping review and taxonomy.

Authors:  Rachel Phillips; Odile Sauzet; Victoria Cornelius
Journal:  BMC Med Res Methodol       Date:  2020-11-30       Impact factor: 4.615

7.  Comparison of statistical methods for the analysis of recurrent adverse events in the presence of non-proportional hazards and unobserved heterogeneity: a simulation study.

Authors:  Noel Patson; Mavuto Mukaka; Lawrence Kazembe; Marinus J C Eijkemans; Don Mathanga; Miriam K Laufer; Tobias Chirwa
Journal:  BMC Med Res Methodol       Date:  2022-01-20       Impact factor: 4.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.